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Nephropathy and Other Topics
ZACHARY T. BLOOMGARDEN, MD
T
his is the eighth of a series of articles
based on presentations at the Amer-
ican Diabetes Association (ADA)
Scientiﬁc Sessions held 610 June 2008
in San Francisco, California.
Nephropathy and blood pressure
Burrows et al. (abstract 266) analyzed the
incidence of end-stage renal disease
(ESRD) in individuals with diabetes, us-
ing data from the U.S. Renal Data System
and estimates of the U.S. population with
diabetes from the National Health Inter-
view Survey, and found that although the
number of diabetic individuals beginning
treatment for ESRD increased from
17,728 in 1990 to 45,951 in 2005, the
age-adjusted incidences were 299, 343,
and 201 per 100,000 diabetic population
in 1990, 1996, and 2005, respectively,
with decreases in incidence consistently
seen in 2005 among diabetic individuals
aged 45, 45–64, 65–74, and 75
years—perhaps an indication that ESRD
is being successfully prevented. There re-
main important areas for intervention.
Kim et al. (abstract 748) studied 3,239
Pima Indians aged 5–19 years. Mi-
croalbuminuria and macroalbuminuria
were found in 7 and 1% of nondiabetic
and in 29 and 2% of diabetic children,
respectively. Regression to normoalbu-
minuria was found in 76% of nondiabetic
but only 20% of diabetic youth, whereas
progression to macroalbuminuria was
seen at annual rates 1% in nondiabetic
youth with microalbuminuria but 4 and
12%indiabeticpatientswithalbumin-to-
creatinine ratios 30–100 and 100–300
mg/g, respectively. Orchard and Costa-
cou (abstract 973) compared 208 type 1
diabetic patients with intermittent versus
persistent microalbuminuria and found
thelattergrouptobe14timesmorelikely
to progress to macroalbuminuria. Persis-
tent microalbuminuria was associated
with higher A1C, systolic blood pressure,
and pulse. Cignarelli et al. (abstract 734)
reported that among 407 type 2 diabetic
patients, there were 55 subjects with glo-
merular ﬁltration rate (GFR) 60 ml/min
of whom 76% were normoalbuminuric.
Although A1C, lipids, statin use, and gly-
cemic treatment were similar in those
with GFR 60 vs. 60 ml/min, the
former were older with body weight 67
vs. 82 kg and diabetes duration 14 vs. 10
years. An et al. (abstract 743) studied 562
diabetic patients and reported that 151
had Modiﬁcation of Diet in Renal Disease
(MDRD) GFR 60 ml/min of whom 44
had normoalbuminuria. Similarly, of
those not treated with renin-angiotensin
systeminhibitors,18of51withGFR60
ml/min had normoalbuminuria. Given
this frequency, the investigators sug-
gested normoalbuminuria to be an early
stageofdiabeticnephropathy,althoughit
might also indicate renal disease. In a
study of 2,099 Pima Indian type 2 dia-
beticpatients,Pavkovetal.(abstract736)
reported that among those with MDRD
GFR 60 ml/min per 1.73m
2 in 1982–
1988 vs. 2001–2006, the proportion of
subjects with normoalbuminuria in-
creased from 9 to 18%. Improved antihy-
pertensive therapies might be in part
responsible.
Katayama et al. (abstract 721) fol-
lowed 1,558 type 2 diabetic patients with
urinealbumin150mg/gcreatininefor8
years. Progression to macroalbuminuria
was2.7-and5.8-foldmorelikelyinthose
with A1C 7–9 and 9%, respectively,
compared with A1C 7%. Those with
systolic blood pressure 120–140 and
140 mmHg had 2.3- and 3.6-fold
greater likelihood of progression than
those with systolic blood pressure 120
mmHg. Cigarette use was an additional
risk factor. Of those with microalbumin-
uria, 30% became normoalbuminuric,
suggesting beneﬁts of early and intensive
blood pressure- and glucose-lowering
treatment.
Genes and nephropathy
Kankova et al. (abstract 369) determined
polymorphisms in genes of the pentose




tients with versus without nephropathy,
ﬁnding a speciﬁc TKT haplotype to be as-
sociated with more rapid nephropathy
progression and with a lower thiamine
level. Astudy of thiamine supplementation
in diabetic patients with this haplotype
would be of great interest. Marcovecchio et
al. (abstract 370) reported that levels of
albuminuria among 933 diabetic patients
aged 10–18 years were associated with a
polymorphism of the gene encoding
ELF1,atranscriptionfactorregulatingthe
expression of immune system and vascu-
lar genes.
Advanced glycation end products
Uribarri et al. (abstracts 255 and 371)
found that in vitro expression of the ad-
vanced glycation end product receptor 1
(AGER1)—involved in advanced glyca-
tion end product (AGE) removal and pre-
vention of AGE-induced inﬂammation
and oxidative stress—increased with
2-daybutdecreasedwith14-dayAGEex-
posure, particularly to methylglyoxal. In
diabetic patients and in nondiabetic pa-
tientswithchronickidneydisease,mono-
nuclear cell AGER1 levels were also
decreased. AGER1 correlated with serum
AGE levels in normal individuals, but pa-
tients with diabetic or nondiabetic
chronic kidney disease had lower mono-
cyte AGER1 despite higher AGE levels,
suggesting a potential therapeutic target.
Cai et al. (abstract 256) from this group
showed an association between mito-
chondrial oxidant stress and AGEs in
vitro and that oxidant stress was de-
creased in aortic endothelial cells overex-
pressing AGER1. Zheng et al. (abstract
745) and Zhang et al. (abstract 706) from
this group overexpressed AGER1 in
nondiabetic and streptozotocin-
induced diabetic mice, showing re-
duced AGE and 8-isoprostane levels in
the nondiabetic and reduced serum with
increased urinary AGE levels in the dia-
betic animals overexpressing the recep-
tor, with lessening of both histological
evidence of diabetic nephropathy and re-
nalcorticaltransforminggrowthfactor-,
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renal disease. Mice overexpressing
AGER1 were resistant to renal tubular in-
jury and endoplasmic reticular stress
caused by the antibiotic and glycoprotein
biosynthesis inhibitor tunicamycin and,
interestingly, required a higher dose of
streptozotocin to cause diabetes, suggest-
ingthatAGER1inductionmaybeaprom-
ising target for pharmacological research.
Coughlan et al. (abstract 763) mea-
sured carboxymethyllysine in 263 dia-
betic patients, ﬁnding those with micro-
and macroalbuminuria to have urinary
levels 30–300 and 200–1,000 times
higher than those with normoalbumin-
uria, respectively, whereas serum levels
did not correlate with the degree of renal
dysfunction.
Kennedy et al. (abstract 728) admin-
istered GLY-230 (Glycadia Pharmaceuti-
cals), an inhibitor of nonenzymatic
glycation of albumin, to 21 diabetic and
21 nondiabetic subjects, reducing gly-
cated albumin without changing A1C in
the diabetic patients. Among diabetic pa-
tients with albuminuria, urine albumin
excretion decreased from 69 to 30 mg/g
creatinineandexcretionofthetransmem-
brane podocyte protein nephrin, which
reﬂects damage to the ﬁltration barrier,
decreased 41%.
Other markers
Schernthaner et al. (abstract 372) com-
pared 138 type 2 diabetic patients with
normo-, micro-, and macroalbuminuria
andwithsimilarage,durationofdiabetes,
A1C, BMI, blood pressure, creatinine,
and lipids, ﬁnding reduction in periph-
eral blood endothelial progenitor cells by
29and73%,respectively,inthelattertwo
groups, without change in total circulat-
ing progenitor cells. In multivariate anal-
ysis, diabetes duration, cardiovascular
disease, and particularly the degree of al-
buminuria were independently associ-
ated with endothelial progenitor cell
number.
Kimura et al. (abstract 764) studied
serum cystatin C as a diagnostic marker
for renal insufﬁciency in Japanese type 2
diabetic patients. The correlation coefﬁ-
cient was 0.85 of cystatin C with GFR
calculated using the MDRD formula,
whereas there was no signiﬁcant correla-
tion with serum parathyroid hormone.
Receiver operating characteristic curves
showed considerably greater sensitivity
and speciﬁcity of cystatin C than of para-
thyroid hormone for stage 2 and stage 3
chronic kidney disease. Satoh et al. (ab-
stract 717) followed 50 hypertensive and
50 normotensive type 2 diabetic patients
with microalbuminuria for 2 years and
found that cystatin increased gradually
while there was no signiﬁcant change in
serum creatinine, suggesting the former
to be useful in longitudinal follow-up as
well as in cross-sectional studies. The re-
lationship may be complex, however, as
Naour et al. (abstract 1762) reported that
cystatin C mRNA is highly expressed in
adipose tissue with doubling of expres-
sion in obese versus lean patients’ subcu-
taneous fat. Cystatin C levels increased
with increasing obesity and correlated
with carotid intima-media thickness
(IMT) in obese adults and children.
LeCaire et al. (abstract 919) reported that
cystatin C was inversely associated with
MDRD GFR. Cystatin C but neither GFR
nor creatinine was associated with albu-
minuria and with carotid IMT in this
study, although Jimenez-Corona et al.
(abstract 918) did ﬁnd an association be-
tween carotid IMT and creatinine clear-
ance. Evidence that cystatin C may not be
ideal for renal function estimation was re-
ported by Costacou et al. (abstract 733).
Factors associated with progression to re-
nalfailureortransplantationover16-year
follow-up in 35% of 118 type 1 diabetic
patients with macroalbuminuria were as
follows: longer diabetes duration, greater
prevalence of hypertension, lower creati-
nine clearance, and higher non–HDL
cholesterol, cystatin C, albuminuria, adi-
ponectin,andC-reactiveprotein.Atyears
14 through 10, there were, however,
no differences in cystatin C, whereas the
creatinine clearance was lower in the
groupultimatelydevelopingrenalfailure,
suggesting that the latter measure may
have greater clinical utility.
Joh et al. (abstract 711) administered
-lipoic acid and the aldose reductase in-
hibitor ﬁderestat to streptozotocin-induced
diabetic rats and found reduction in albu-
minuria and in vascular endothelial
growthfactorexpression.Kumeetal.(ab-
stract705)administeredexenatideversus
control treatment to db/db mice and re-
ported reduction in obesity, glycemia,
and hypertension, as well as attenuation
of the development of albuminuria and
renal mesangial expansion and macro-
phage inﬁltration. Tong et al. (abstract
724) followed 6,004 type 2 diabetic pa-
tientsforamedianof5years.Inmultivar-
iate analysis, statin use was associated
with a 25% reduction in likelihood of a
decrease in MDRD GFR to 60 ml/min,
whereas there were no protective effects
of ﬁbrate treatment, controlling for age,
sex, smoking status, diabetes duration,
blood pressure, BMI, A1C, LDL and HDL
cholesterol, albuminuria, use of insulin,
angiotensin-directed treatment, and
other microvascular and macrovascular
complications.
De Galan et al. (abstract 752) studied
whether effects of perindopril-indapam-
ideversusplaceboonrenaloutcomesvary
according to baseline blood pressure and
investigated the association between
achieved follow-up blood pressure and
risk of renal events in the Action in Dia-
betes and Vascular disease: preterAx and
diamicroN-MR Controlled Evaluation
(ADVANCE) study of 11,140 type 2 dia-
betic participants. Blood pressure de-
creasedfrom145/81to140/77vs.135/75
mmHg in the control versus intervention
groups, the latter having a 21% reduction
inthecompositeofnew-onsetmicroalbu-
minuria, new-onset macroalbuminuria,
doubling of creatinine 200 mol/l,
ESRD, or renal death, with similar beneﬁt
for the components of the end point and
similar beneﬁt of treatment in subgroups
ranging from baseline systolic/diastolic
120/70 to 90/160 mmHg. With
achieved blood pressure as low as 106/62
mmHg,therewasalinearrelationshipbe-
tween the logarithm of achieved blood
pressure and renal events, suggesting
beneﬁt at levels below current recom-
mended targets. Emanuele et al. (abstract
742) studied baseline associations with
nephropathy among the 1,792 partici-
pants in the Veterans Affairs Diabetes
Trial (VADT), which excluded subjects
with baseline serum creatinine 1.6 mg/
dl. Lower GFR was associated with age,
diabetes duration, higher C-peptide lev-
els, higher BMI (but lower waist-to-hip
ratio), a history of cerebrovascular dis-
ease, and retinopathy. Greater degrees of
albuminuria were associated with higher
A1C,systolicbloodpressure,totalcholes-
terol, and ﬁbrinogen; lower HDL choles-
terol; and retinopathy and coronary
disease.
Lipid treatment
Drexel et al. (abstract 878) studied 491
statin-treated patients with stable coro-
nary heart disease, of whom 116 had type
2 diabetes. Presumably because all pa-
tients were intensively treated, LDL cho-
lesterol and apolipoprotein B were not
predictors of events, but low HDL choles-
terol and apolipoprotein A1, small LDL
particle diameter, and high triglyceride
levels were associated with events, sug-
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lipid treatment targets. Devaraj and Jialal
(abstract 258) isolated HDL from fasting
blood from six type 1 diabetic and six
nondiabetic subjects and found that the
former had decreased capacity to efﬂux
cholesterol from macrophages, increased
lipid peroxides, and decreased paraoxo-
nase activity (a mediator of enzymatic
protection of LDL against oxidative mod-
iﬁcation). Type 1 diabetic HDL increased
monocyte chemotaxis, failed to protect
against adhesion molecule activity, and
contained increased levels of serum amy-
loid A, suggesting that HDL from type 1
diabetic patients may be dysfunctional
and proinﬂammatory, explaining the often
observed paradox of high HDL cholesterol
in these patients despite development of
cardiovascular disease. Richards et al. (ab-
stract 866) analyzed the information value
of fasting versus nonfasting lipids in 22
type 2 diabetic and 25 nondiabetic pa-
tients and reported that nonfasting LDL
cholesterol was 9 mg/dl lower than fast-
ing,whereasnonfastingtriglyceridelevels
werehigher.Fourpatientshadnonfasting
and two had fasting triglyceride levels
400 mg/dl. Nonfasting results failed to
identify one patient requiring additional
treatment (a false negative) but misiden-
tiﬁed no patients (no false positives), sug-
gesting high sensitivity and a reasonable
alternative to fasting lipid determination,
particularly when testing would other-
wise be omitted as a result of nonfasting
status.
Statins
Foody et al. (abstract 263) used claims
data from 92 U.S.-managed care plans to
identify cardiovascular events in 46,076
diabetic patients without cardiovascular
disease who newly initiated atorvastatin
(10 or 20 mg) versus simvastatin (20 or
40 mg). Over a 1.5-year follow-up, re-
ported cardiovascular event rates were
3.35 versus 4.45 per 100 person-years
with a signiﬁcant 12% lower event rate,
adjusting for age, sex, type of health plan,
payer type, geographic region, calendar
year of statin initiation, physician spe-
cialty, comorbidities, concomitant thera-
pies,andpriorhealthcarecost.Ofcourse,
such epidemiological studies should only
be regarded as hypothesis generating be-
cause the apparent better outcome with
atorvastatin could reﬂect differences in
patients (those choosing brand versus
generic or those more versus less inﬂu-
enced by direct-to-consumer marketing)
or in physician choices (using simvastatin
for somewhat more sick patients).
Niacin
Bays et al. (abstract 86) reported effects of
the combination of extended release nia-
cin(2gdaily)withorwithoutlaropiprant
to reduce ﬂushing versus placebo, in 600
subjects with versus 787 without meta-
bolic syndrome—the combination show-
ing 18 vs. 20% reduction in LDL
cholesterol, 22 vs. 17% increase in HDL
cholesterol, and 28 vs. 17% reduction in
triglyceride levels, with 2–4 mg/dl in-
creaseinfastingglucoselevel(withoutin-
creasing or reducing the lipid effects of
niacinbyaddinglaropiprant).Theoverall
study has been published and reported
that 10.2% of patients stopped niacin
with laropiprant versus 22.2% with nia-
cin monotherapy (1). Plaisance and Judd
(abstract 1395) administered niacin ver-
sus placebo to rats and found elevation in
adiponectin levels, with increased adi-
ponectin secretion from adipocytes incu-
bated with niacin for 24 h in vitro—
suggesting a potential mechanism of
beneﬁt,althoughnotconcordantwiththe
glucose-raising effect of the agent.
Fibrates
Li et al. (abstract 475) studied 45 hyper-
triglyceridemic individuals with type 2
diabetes or impaired glucose tolerance.
Fenoﬁbrate (200 mg daily) decreased
fasting insulin 30% with a 30% increase
in the acute insulin response to intrave-
nous glucose, with deterioration in both
indexes in a placebo group. Jones et al.
(abstract 85) treated 276 type 2 diabetic
patients who had LDL cholesterol 130
mg/dl, triglyceride levels 150 mg/dl,
and HDL cholesterol 40 mg/dl (50
mg/dl for female subjects) with the feno-
ﬁbratepreparationABT-335,rosuvastatin
(10–40 mg), or the combination for 12
weeks. ABT-355 increased HDL choles-
terolby15%andreducedtriglyceridelev-
els by 34% and LDL cholesterol by 6%;
rosuvastatin (10 and 20 mg) increased
HDL cholesterol by 7 and 12%, reduced
triglyceride levels by 28 and 27%, and
reduced LDL cholesterol by 44 and 45%;
however, the combination had a less than
additive effect at the rosuvastatin 10- and
20-mg doses in increasing HDL choles-
terolby21and18%andreducingtriglyc-
eride levels 45 and 42%, with LDL
reductionsof37%atbothdoses(lessthan
the effect of rosuvastatin alone), suggest-
ing that the use of the combination in di-
abetic patients should be highly selective.
Calorie restriction
Andrew Dillin (La Jolla, CA) noted that
lifelong calorie restriction by half (with-
out malnutrition) improves longevity in
every animal model studied, from worms
to rodents to nonhuman primates. The
DAuer Formation (daf)-16 insulin/IGF-1
analog gene is not required for diet restric-
tion in worms and ﬂies. Diet restriction–
mediated longevity in the roundworm
Caenorhabditis elegans is independent of
FOX01, with a transcriptional coregula-
tor smk-1, a mitogen-activated protein ki-
nase homolog that speciﬁcally regulates
longevity and stress resistance (2). Smk-1
has effects analogous to those of peroxi-
some proliferator–activated receptor-
coactivator (PGC)-1 and appears to part-
ner with daf-16 in insulin signaling as
well as in mediating effects of dietary re-
striction, perhaps involving an alternate
forkhead-like transcription factor to
FOX01, pha-4—the worm ortholog of
the Foxa gene. In mammals, Foxa1 binds
and activates genes expressed in foregut
endoderm–derived lineages and is re-
quiredforfetaldevelopment,butgenede-
letion in adulthood shows that Foxa1
function later in life is to regulate glucose
homeostasis.Pha-4similarlyhasdevelop-
mentalfunctionearlyintheC.eleganslife
cycle; during adult life, it mediates the
longevity effect of dietary restriction in a
fashion speciﬁc to dietary restriction,
whereas daf-16 is more speciﬁc to the re-
sponse for insulin/IGF-1. Pha-4 expres-
sion increases with diet restriction,
although its subcellular localization does
not change, and overexpression of pha-4
extends life span on ad libitum diet, par-
ticularly with deletion of daf-16 (3).
Anne Brunet (Palo Alto, CA) discussed
FOX0 transcription factors in insulin and
nutrient signaling as components of molec-
ularmechanismsoflongevityandnotedthe
progressive increase in life span of a vari-
ety of species with reductions in calorie
intake by 25 to 65% (4) and with reduc-
tion in risk of cancer, increased perfor-
mance in learning and memory, and a
varietyofadditionaleffectssuggestingde-
lay in aging and age-related traits. Given
that insulin levels decrease with dietary
restriction and because reducing insulin
action extends life span in worms, ﬂies,
mice, and perhaps humans, studies of the
insulin signaling pathway have been im-
portant. Insulin and IGF-1 act via the
FOX0 family of forkhead transcription
factors (with pyruvate dehydrogenase ki-
nasephosphorylatingFOX0),blockingits
translocation to the nucleus and leading
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nonphosphorylated state enters the
nucleus and may lead to transcription of
antiaging genes. FOX0 interacts with
SIRT1—the mammalian homolog of the
sirtuin (silent information regulator) en-
zymes—a histone/protein deacetylase
that has been linked to the prolongation
of life span caused by caloric restriction.
There are seven mammalian sirtuins:
SIRT1 and SIRT2 expressed mainly in the
brain; SIRT3, SIRT4, and SIRT5 active in
mitochondria; SIRT6 active in the nu-
cleus; and SIRT7 active in the nucleolus
and activating RNA polymerase I tran-
scription. SIRT1 levels increase with di-
etary restriction, potentially activating
target genes leading to stress resistance
and longevity. The genes mediating the
effect of dietary restriction may involve
AMP-activated protein kinases (AMPKs)
that may be a cellular energy sensor acti-
vated by low leptin, low energy, low glu-
cose,exercise,andbiguanides.AMPKcan
integrate a wide variety of stimuli by its
exquisiteabilitytosensetheAMP/ATPra-
tio, with increase in AMP triggering
change in the  catalytic subunit of
AMPK, activating acetyl-CoA carboxy-
lase, with multiple effects on lipid and
protein synthesis. In C. elegans, with re-
duced nutrition there is extended life
span and amelioration of the decline in
physical activity with age, associated with
increased AMP/ATP ratio, requiring
AMPK. Overexpression of AMPK in C. el-
egans leads to increased life span and
stress resistance. AMPK may directly
phosphorylate daf-16 in C. elegans and
FOX01inmammals,extendinglongevity.
Another forkhead transcription factor
FOX03 is also phosphorylated with in-
creases in AMPK and may have roles in
stress resistance and energy metabo-
lism. AMPK activators such as met-
formin then may be beneﬁcial for
nondiabetic life span (5).
AnumberofreportsattheADAmeet-
ingprovidedinformationoneffectsofcal-
orie restriction. Zheng et al. (abstract
1263) reported that 40% calorie restric-
tionofobeseZukerratsimprovedhepatic
insulin sensitivity in association with re-
duction in extracellular signal-regulated
kinase activity. Jing et al. (abstract 145)
studied Sirt3, expression of which is de-
creased in skeletal muscle of streptozoto-
cin-induced diabetic mice, showing
decreased hepatic and skeletal muscle ex-
pression on a high-fat diet. Small interfer-
ing RNA administration to decrease Sirt3
in vitro in myoblasts reduced insulin-
stimulated phosphorylation of Akt and
mitogen-activated protein kinase because
of decreased insulin receptor substrate
(IRS)-1tyrosinephosphorylation;oxygen
consumption induced by mitochondrial
uncoupling was signiﬁcantly decreased,
AMPK activity was inhibited, and PGC-1
and other stress markers were increased.
Suchankova et al. (abstract 1492) studied
hepatocytes overexpressing PGC-1 (a
SIRT1 target gene) and found reduc-
tion in SIRT1 activity with high glucose
concentrations increasing acetylated
PGC-1, as did the SIRT1 inhibitor nico-
tinamide that also decreased the phos-
phorylated form of AMPK, implying that
SIRT1 may regulate AMPK and that the
activity of SIRT1 may be decreased by hy-
perglycemia. Banks et al. (abstract 1387)
studied mice overexpressing SIRT1 and
reportedimprovedglucosetolerancewith
increased adiponectin and reduced meta-
bolic rate as well as decreased food intake
to maintain body weight. Milne et al. (ab-
stract 1907) and Perni et al. (abstract 540)
studied effects of small molecule SIRT1 ac-
tivators, oxazolopyridines, and isoazathia-
zoles (IATs) and found inhibition of
inﬂammation in vitro in human monocytes
and improved insulin sensitivity, with re-
duced inﬂammatory gene expression in a
high-fat diet–induced obesity model with
theagentsSRT2183andSRT1720.TheIAT
SIRT1 activator SRT2104 demonstrated
signiﬁcantglucose-loweringactivityinboth
theob/obanddietaryobesitymousemodels.
Resveratrol—a plant chemical pro-
duced under attack by bacteria or fungi,
present in wine—extends the life span of
several invertebrates and vertebrates and
counteracts high-fat diet–induced insulin
resistance in mice, perhaps by activating
SIRT1andPCG-1.Knightetal.(abstract
1321) extended studies showing that hy-
pothalamic resveratrol suppressed he-
patic glucose production and increased
insulin sensitivity by central SIRT1 acti-
vation. Systemic resveratrol administra-
tion increased insulin sensitivity by
reducing hepatic glucose production
withoutincreasingperipheralglucoseuti-
lization. Inhibition of hypothalamic Sirt1
activity reduced the effect of systemic res-
veratrolbyincreasinghepaticglycogenol-
ysis. Sanli et al. (abstract 572) reported
that resveratrol reduced free fatty acid–
induced insulin resistance in vitro; Dan-
dona et al. (abstract 346) administered
resveratrol (100 mg daily) versus placebo
to 16 healthy normal-weight subjects, re-
ducing monocyte inﬂammatory and mi-
togenic gene expression while increasing
IRS-1 expression; and Kitada et al. (ab-
stract 753) found that db/db mice showed
reduction in hyperglycemia and in albu-
minuria and mesangial expansion, al-
though Kasinath et al. (abstract 738)
reported that resveratrol improved renal
injury in streptozotocin-induced diabetic
rats by stimulating AMPK rather than by
affecting SIRT1 activity.
Polsky et al. (abstract 102) analyzed
the effect of alcohol consumption in
3,175participantsintheDiabetesPreven-
tion Program followed for 3.2 years and
found that those receiving metformin or
the intensive lifestyle intervention had
lower rates of diabetes development with
ingestion of one or more alcoholic bever-
ages daily, controlling for age, sex,
weight, ethnicity, C-reactive protein, ex-
ercise, caloric intake, insulin sensitivity
and secretion, and fasting glucose. Kim
and Reaven (abstract 354), however, ad-
ministered 20–30 g of alcohol (red wine
orvodka)dailyfor1monthto20insulin-
resistant subjects and reported only mod-
est and nonsigniﬁcant increase in insulin
sensitivity, with a 9% increase in HDL
cholesterol.
Biology of taste and taste receptors
CharlesZuker(LaJolla,CA)discussedthe
biologyoftasteandtastereceptors(6).To
understand the signaling and coding
mechanisms by which the brain encodes
and decodes taste stimuli, we need to un-
derstand “how the tongue knows” what it
has just tasted and, next, “how the brain
knowswhatthetongueknows.”Themain
tastes are sweet, sour, bitter, salty, and
umami (the taste of monosodium gluta-
mate). Taste contributes to the overall en-
joymentandpleasureofamealinhumans
butplaysmorebasicrolesinotherspecies
mediating behaviors, with sweet acting as
a measure of calories, salt electrolyte bal-
ance, umami amino acids, sour as key to
preventingingestionofspoiledfoods,and
bitter preventing ingestion of toxins.
Nearly every plant toxin tastes bitter to
humans. The basic units of taste are taste
receptor cells, which are organized in
taste buds and in turn organized in the
tongue in taste papillae of various types.
Every taste bud in all areas of the tongue
containsreceptorsforallbasictastes,with
the posterior tongue enriched with bitter
receptors, which trigger the gag reﬂex.
The attractive taste modalities are
sweet and umami, mediated by combina-
tions of three G-protein–coupled recep-
tor units T1R1, T1R2, and T1R3, with
umamiasacombinationofT1R1	T1R3
Bloomgarden
DIABETES CARE, VOLUME 32, NUMBER 8, AUGUST 2009 e97and sweet T1R2 	 T1R3, whereas bitter
taste recognition involves the type 2 G-
protein–coupled taste receptor. Salty
taste may involve epithelial Na channels
similar to those in the kidney, and sour
taste may involve intracellular acidiﬁca-
tionactingonspeciﬁcmembraneproteins
(7). Electrophysiological measurement
after taste challenge assays increase in ac-
tion potential response to one or another
of the ﬁve basic tastes. Deletion of T1R1
or T1R3 eliminates the umami response,
T1R3 also sweet, and T1R2 eliminates
sweet taste providing evidence of the G-
protein–coupled receptor selectivity of
receptor rearrangements. Bitter is related
to the rhodopsin light receptor; there are
24 human and 33 rodent bitter receptors,
functioning to give information about
speciﬁcbittertastes.Sequencedifferences
in taste receptors underlie taste selectivity
and sensitivity differences between spe-
cies. Rodents, for example, do not taste
aspartameandintensivelysweetproteins,
whereas introduction of the human re-
ceptor into a mouse can give rise to rec-
ognition of these as speciﬁc taste signals.
Taste cells are segregated by type at the
periphery of the tongue, with speciﬁc
cells dedicated to speciﬁc taste qualities.
Animals lacking entire taste qualities can
detect, recognize, and respond normally
to the remaining modalities, and experi-
mentsintroducinganotherreceptorintoa
cell type will lead to activation of the typ-
icalstereotypedbehaviorofthatcelltype–
speciﬁc activation.
After taste signals are generated, neu-
rotransmitters are secreted acting both on
neighboring taste cells, suggesting local
information processing, and on sensory
afferent ﬁbers. Cells for sweet, bitter, and
umami taste stimuli secrete ATP that acts
as a neurotransmitter, whereas sour and
salt taste cells release other neurotrans-
mitters including serotonin. At the brain
level, understanding of taste recognition
is more preliminary; however, there is ev-
idence of selective distribution of unique
receptors from speciﬁc tastes in speciﬁc
cortical areas, with mixtures of several
tastes activating certain groups and inac-
tivatingothergroupsofcorticalcells.This
is not, Zuker commented, the full story of
how the brain “knows” speciﬁc signals,
but it is a beginning.
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